|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||17.68 - 18.00|
|52 Week Range||12.10 - 19.50|
|Beta (3Y Monthly)||0.04|
|PE Ratio (TTM)||50.06|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Genmab (GNMSF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Genmab A/S (OTC PINK: GMXAY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 6:00 PM Eastern Time. To listen ...
This analysis is intended to introduce important early concepts to people who are starting to invest and want to learn about Return on Equity using a real-life example. Genmab A/SRead More...
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health toRead More...
In this article I am going to calculate the intrinsic value of Genmab A/S (CPSE:GEN) using the discounted cash flows (DCF) model. Anyone interested in learning a bit more aboutRead More...
Italy's FTSE MIB benchmark index fell 2.1 percent to its lowest level since early March, while the pan-European STOXX 600 index shed 0.3 percent on a day when activity was limited by market holidays in Britain and the United States. The Italian index had risen as much as 2 percent in early trade after Italy's president vetoed the Five-Star and League parties' choice of a eurosceptic economy minister.
European stocks fell Monday, as investors monitored signs of thawing tensions between the U.S. and North Korea and reacted to renewed political turmoil in Italy.